Icon
+91 94997 68112
Login Register

Soliris - (300 mg; Injection)

Eculizumab Alexion Pharma
300 mg; Injection
Less Than $1000 mn
None
Less Than 5
Less Than 5
 None
None None
Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Soliris is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy
Yes
***** ***** * *** *** ****** '***, '*** *** '***. *****, ******* *** ***** ****** **** **** ******* (**********),********* ** ***** ** **********, ***** *** ****** *** ******* ** *** *, **** ** ******* ***** **** *************. (*****://***.***.***/**?***=/********/*****/****/******/******************/****-********.***)
Soliris Patent 1 Patent 2 Patent 3
***** ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ******* **** ** *** *, ****
  1. *** **, **** : ***** ***** * *** *** ****** '***, '*** *** '***
  2. *** **, **** : ******* *** ***** ****** **** **** ******* (**********),********* ** ***** ** **********, ***** *** ****** *** ******* ** *** *, **** ** ******* ***** **** *************.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.